New Pharmaceutical Reform Alliance Poll: Americans Agree on One Thing – Rein in Big Pharma

Key Takeaways

• 89% of voters back U.S. prescription‑drug pricing reform
• 68% say drug prices rose in the past year
• 94% blame pharmaceutical companies for high healthcare costs
• 87% support international price‑matching to lower drug prices
• 77% more likely to vote for candidates who fight Big Pharma

Pulse Analysis

The latest Pharmaceutical Reform Alliance poll arrives at a moment when Americans are grappling with an affordability crisis that extends beyond rent and groceries to life‑saving medicines. By surveying a demographically balanced sample of 1,524 voters, the study captures a clear signal: price inflation is not just a partisan talking point but a shared hardship. Voters across the political spectrum recognize that prescription‑drug costs have surged, attributing the spike to corporate profit motives and executive compensation. This perception creates fertile ground for policy initiatives that directly target pricing mechanisms.

Policy proposals highlighted in the poll enjoy unprecedented backing. International price‑matching, which would align U.S. drug prices with those of peer nations, received 87% support, while reforms to accelerate patent expirations and curb direct‑to‑consumer advertising each cleared the 80% threshold. Such figures suggest that legislators have a robust mandate to pursue reforms that have historically faced industry resistance. The bipartisan nature of the support—over 90% of Republicans and a solid majority of Democrats—means that drug‑pricing legislation could transcend typical partisan gridlock, especially as midterm candidates seek to capitalize on voter demand for tangible relief.

For the pharmaceutical industry, the poll signals a potential shift in market dynamics. Heightened political pressure may accelerate the adoption of pricing transparency tools, increase reliance on value‑based contracts, and spur investment in generic and biosimilar development. Meanwhile, advocacy groups like the PRA are likely to leverage these data points to intensify lobbying efforts and shape campaign narratives. Candidates who position themselves as champions against Big Pharma could gain a decisive edge, reshaping electoral strategies and, ultimately, the regulatory landscape governing drug pricing in the United States.